glp-1/gip dual agonist mechanism of action Mechanisms and effects of GLP‐1 receptor agonists and Science Behind GLP 1 GIP

There is no confirmed elevated risk of suicidality, but surveillance remains warranted

Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)

This move comes as these diabetes and weight-loss drugs see explosive demand in India, fueled by rising obesity rates and recent price reductions

Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.